{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-120824","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.244112+00:00","generated_at":"2026-05-21T04:47:09.758552+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rein Therapeutics Q1 net loss $5.5M; Phase 2 IPF trial initiated","bullets":["Net loss $5.5M ($0.25/shr) vs $7.1M ($0.86/shr) year ago; revenue not reported.","Cash $7.4M at Mar 31, plus $5.28M from April warrant/private placement; runway to Sep 2025.","Phase 2 RENEW trial of LTI-03 in IPF initiated; topline interim data expected H1 2026.","Two U.S. patents granted for LTI-03 dry powder formulation (Apr 22, 2025).","R&D expense $3.1M, G&A $2.5M, both down vs prior year on lower legal and LTI-01 costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-120824","json":"https://secwatch.observer/filing/0001193125-25-120824.json","markdown":"https://secwatch.observer/filing/0001193125-25-120824.md","text":"https://secwatch.observer/filing/0001193125-25-120824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525120824/0001193125-25-120824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525120824/d889805d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:47:09.758552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}